BACKGROUND: Preclinical evidence implicates the serotonin receptor 5-hydroxytryptamine 1B (5-HT1B) in the effects of cocaine. This study explores 5-HT1B in humans by examining receptor availability in vivo in subjects whose primary addiction is cocaine dependence (CD) using positron emission tomography. METHODS: Study participants included 14 medically healthy subjects with CD (mean age = 41 ± 6 years) who were compared with 14 age-matched healthy control subjects (mean age = 41 ± 8 years) with no past or current history of cocaine or other illicit substance abuse. Participants underwent magnetic resonance imaging followed by positron emission tomography with the highly selective 5-HT1B tracer, [(11)C]P943, for purposes of quantifying regional binding potential. Voxel-based morphometry and gray matter masking also were employed to control for potential partial volume effects. RESULTS: The [(11)C]P943 positron emission tomography imaging data in nine candidate regions (amygdala, anterior cingulate cortex, caudate, frontal cortex, hypothalamus, pallidum, putamen, thalamus, and ventral striatum) showed significant or nearly significant reductions of regional binding potential in subjects with CD in three regions: anterior cingulate (-16%, p < .01), hypothalamus (-16%, p = .03), and frontal cortex (-7%, p = .08). Voxel-based morphometry showed significant gray matter reductions in the frontal cortex of subjects with CD. After gray matter masking, statistically significant reductions in the [(11)C]P943 regional binding potential were either retained (anterior cingulate, -14%, p = .01; hypothalamus, -20%, p < .01) or achieved (frontal cortex, -14%, p < .01). Whole-brain voxel-wise parameter estimation confirmed these results. Secondary analyses were also significant in some regions for years of cocaine and daily tobacco use. CONCLUSIONS: The reductions found in this study suggest that 5-HT1B receptors may contribute to the etiology or expression of CD and potentially represent a target for medication development.
BACKGROUND: Preclinical evidence implicates the serotonin receptor 5-hydroxytryptamine 1B (5-HT1B) in the effects of cocaine. This study explores 5-HT1B in humans by examining receptor availability in vivo in subjects whose primary addiction is cocaine dependence (CD) using positron emission tomography. METHODS: Study participants included 14 medically healthy subjects with CD (mean age = 41 ± 6 years) who were compared with 14 age-matched healthy control subjects (mean age = 41 ± 8 years) with no past or current history of cocaine or other illicit substance abuse. Participants underwent magnetic resonance imaging followed by positron emission tomography with the highly selective 5-HT1B tracer, [(11)C]P943, for purposes of quantifying regional binding potential. Voxel-based morphometry and gray matter masking also were employed to control for potential partial volume effects. RESULTS: The [(11)C]P943 positron emission tomography imaging data in nine candidate regions (amygdala, anterior cingulate cortex, caudate, frontal cortex, hypothalamus, pallidum, putamen, thalamus, and ventral striatum) showed significant or nearly significant reductions of regional binding potential in subjects with CD in three regions: anterior cingulate (-16%, p < .01), hypothalamus (-16%, p = .03), and frontal cortex (-7%, p = .08). Voxel-based morphometry showed significant gray matter reductions in the frontal cortex of subjects with CD. After gray matter masking, statistically significant reductions in the [(11)C]P943 regional binding potential were either retained (anterior cingulate, -14%, p = .01; hypothalamus, -20%, p < .01) or achieved (frontal cortex, -14%, p < .01). Whole-brain voxel-wise parameter estimation confirmed these results. Secondary analyses were also significant in some regions for years of cocaine and daily tobacco use. CONCLUSIONS: The reductions found in this study suggest that 5-HT1B receptors may contribute to the etiology or expression of CD and potentially represent a target for medication development.
Authors: N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot Journal: Neuroimage Date: 2002-01 Impact factor: 6.556
Authors: Teresa R Franklin; Paul D Acton; Joseph A Maldjian; Jason D Gray; Jason R Croft; Charles A Dackis; Charles P O'Brien; Anna Rose Childress Journal: Biol Psychiatry Date: 2002-01-15 Impact factor: 13.382
Authors: James W Murrough; Shannan Henry; Jian Hu; Jean-Dominique Gallezot; Beata Planeta-Wilson; John F Neumaier; Alexander Neumeister Journal: Psychopharmacology (Berl) Date: 2010-05-18 Impact factor: 4.530
Authors: J A Bouwknecht; J van der Gugten; T H Hijzen; R A Maes; R Hen; B Olivier Journal: Psychopharmacology (Berl) Date: 2001-02 Impact factor: 4.530
Authors: Ponnada A Narayana; Sushmita Datta; Guozhi Tao; Joel L Steinberg; F Gerard Moeller Journal: Drug Alcohol Depend Date: 2010-05-31 Impact factor: 4.492
Authors: O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle Journal: J Cereb Blood Flow Metab Date: 2001-09 Impact factor: 6.200
Authors: Nora D Volkow; Dardo Tomasi; Gene-Jack Wang; Joanna S Fowler; Frank Telang; Rita Z Goldstein; Nelly Alia-Klein; Christopher Wong Journal: PLoS One Date: 2011-02-23 Impact factor: 3.240
Authors: David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson Journal: Neuroimage Date: 2016-02-11 Impact factor: 6.556
Authors: Christopher Pittenger; Thomas G Adams; Jean-Dominique Gallezot; Michael J Crowley; Nabeel Nabulsi; Hong Gao; Stephen A Kichuk; Ryan Simpson; Eileen Billingslea; Jonas Hannestad; Michael Bloch; Linda Mayes; Zubin Bhagwagar; Richard E Carson Journal: J Affect Disord Date: 2016-02-09 Impact factor: 4.839
Authors: Muhammad A Parvaz; Anna B Konova; Greg H Proudfit; Jonathan P Dunning; Pias Malaker; Scott J Moeller; Tom Maloney; Nelly Alia-Klein; Rita Z Goldstein Journal: J Neurosci Date: 2015-02-04 Impact factor: 6.167
Authors: Michael M Havranek; Matthias Vonmoos; Christian P Müller; Jessica R Büetiger; Eve Tasiudi; Lea M Hulka; Katrin H Preller; Rainald Mössner; Edna Grünblatt; Erich Seifritz; Boris B Quednow Journal: Neuropsychopharmacology Date: 2015-05-27 Impact factor: 7.853
Authors: Gustavo A Angarita; Patrick D Worhunsky; Mika Naganawa; Takuya Toyonaga; Nabeel B Nabulsi; Chiang-Shan R Li; Irina Esterlis; Patrick D Skosnik; Rajiv Radhakrishnan; Brian Pittman; Ralitza Gueorguieva; Marc N Potenza; Sjoerd J Finnema; Yiyun Huang; Richard E Carson; Robert T Malison Journal: Addict Biol Date: 2021-12-01 Impact factor: 4.280